Patient Consultation and Support Tools
VOCABRIA + REKAMBYS is a different way to treat HIV-1, so we’ve developed the following tools to help support conversations with your patients around their VOCABRIA + REKAMBYS treatment1,2
Patient Resources
References:
- VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
- REKAMBYS Summary of Product Characteristics. Janssen Healthcare.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-210001v3 I April 2022
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
